RenovoRx Inc.
02/17/2026 | Press release | Archived content
Why Commercial Discipline Starts Long Before Launch
Shaun Bagai is the CEO of RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug-delivery device, targeting high unmet medical needs.
RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing the therapy's toxicities versus systemic intravenous therapy.
RenovoRx Inc. published this content on February 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 04, 2026 at 22:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]